EUCTR2006-001085-17-GB进行中（未招募）1 期
Further development of a new model of GAD: The effect of a clinically effective and non-effective dose of lorazepam on CO2 induced anxiety - Determining the dose effect of lorazepam on CO2 induced anxiety
niversity of Bristol0 个研究点目标入组 18 人开始时间: 2007年6月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •2.Age between 19 and 40 years
- •3.Body weight >60kg.
- •4.No abnormality on clinical examination, including a history of presence of cardiac, ophthalmologic, gastro-intestinal, hepatic, or renal disease or other condition known to increase risk of side effects.
- •5.No clinically significant abnormality on clinical chemistry or haematology or ECG examination at screening prior to study.
- •6.Negative urine drug screen at the clinical screening and on the day of each inhalation session (4 sessions in all).
- •7.No abuse of alcohol defined as an average intake of greater than 21 units per week or 3 units per day. One unit is equivalent to a half pint of beer or 1 measure of spirits or 1 glass of wine.
- •8.If participants usually consume a caffeinated drink in the morning they will be asked not to consume more than one cup of their normal volume and not to consume it within 2 hours of the beginning of the session.
- •9.No history or presence of neurological or psychiatric conditions (e.g. stroke, traumatic brain injury, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, schizophrenia, major depression, generalise anxiety disorder etc.).
- •10.No history of panic attacks or severe anxiety.
- •11.No history of claustrophobia.
- •12.No history of, or current condition of, migraine headaches.
- •13.Subjects will be instructed to eat a light meal at least 1 hour before attending the research unit.
- •14.No previous experience of the CO2 procedure
- •15.A negative breathalyzer test on the day of the test session (4 sessions in all)
- •16.Subjects have given informed consent
- •17.Do not have needle or blood phobia.
- •18.Non smoker or light smoker (< 5 cigarettes per day ). Participants should not smoke for 2 hours prior to study visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Are female
- •2.Have received prescribed medication within 14 days prior to the first dosing (drug or placebo), which in the opinion of the medical consultant conducting the screening may interfere with the study procedures or compromise safety.
- •3.Have received over-the-counter (OTC) medicine within 48 hours before the beginning of the session. Subjects who have taken OTC medication may still be entered into the study, if, in the opinion of the medical consultant, the medication received will not interfere with the study procedures or compromise safety.
- •4.Have a personal, or have a close family member with, a history of panic disorder or an anxiety disorder.
- •5.Have participated in a trial with any drug within 84 days before start of study.
- •6.Have a positive urine test for psychoactive drugs e.g. cannabis.
- •7.Have a positive alcohol breath test (> 20mgl 100 ml of blood) on the morning of the test day.
研究者
相似试验
已完成
不适用
Further development of a new model of generalised anxiety disorder: effects on processing of emotional materialISRCTN76669810Record Provided by the NHSTCT Register - 2007 Update - Department of Health20
尚未招募
不适用
The retrospective exploration for the new type of medicines for congestive heart failurecongestive heart failureJPRN-UMIN000042693Yokohama City University Medical Center60
招募中
不适用
The development of a new method for evaluation of glaucoma (The relationship between ocular circulation and neural activity in glaucoma patients)glaucomaJPRN-UMIN000023960Asahikawa Medical University50
已完成
不适用
Development and exploration of an AI model to classify healthy subject and suspected schizophrenia patient based on free conversations with medical staffSchizophreniaJPRN-jRCT1030210514Yuichiro Tsutsumi150
招募中
不适用
Development and exploration of an AI model to classify schizophrenia with signs of relapse and schizophrenia with no signs of relapse based on free conversations with medical staffSchizophreniaJPRN-jRCT1030220320Toyoshiba Hiroyoshi100